Blog
Clinical evidence insights, methodology deep-dives, and the latest in clinical decision support from the Ailva team.
Immunotherapy Checkpoint Inhibitors: A Clinical Guide for Oncologists
PD-1, PD-L1, and CTLA-4 inhibitors have transformed solid tumor oncology. This guide covers approved indications, biomarker selection, immune-related adverse event management, and combination strategies across major tumor types.
MASH (Metabolic-Associated Steatohepatitis): The New Treatment Landscape
With resmetirom (Rezdiffra) becoming the first FDA-approved therapy for MASH in 2024, the treatment paradigm has shifted fundamentally. This guide covers the evidence, patient selection, and the pipeline of emerging therapies for gastroenterologists and hepatologists.
Migraine Prevention: CGRP Inhibitors, Comparative Efficacy, and Treatment Selection
CGRP-targeting therapies have transformed migraine prevention, offering the first mechanism-specific preventive class. This review compares the four anti-CGRP monoclonal antibodies and two gepant preventives, covering efficacy data, onset of action, and practical selection for episodic and chronic migraine.
Chronic Pain Management: Multimodal Non-Opioid Approaches and Evidence Review
Multimodal non-opioid pain management has become the standard of care for chronic non-cancer pain. This review covers the evidence for gabapentinoids, SNRIs, topical agents, interventional procedures, and structured physical rehabilitation, with practical prescribing guidance for primary care and pain specialists.
Gout Management: Treat-to-Target Urate Strategy and IL-1 Inhibitor Therapy
Treat-to-target urate-lowering therapy (ULT) reduces gout flares, tophi burden, and joint damage. This review covers allopurinol dosing optimization, febuxostat cardiovascular safety data, and the role of pegloticase and IL-1 inhibitors in refractory disease.
Hepatitis C: Pan-Genotypic DAA Regimens, Treatment Simplification, and Cure Rates
Direct-acting antivirals (DAAs) have transformed hepatitis C into a curable disease with SVR rates exceeding 95% across all genotypes. This review covers current pan-genotypic regimens, treatment simplification for non-cirrhotic patients, and management of decompensated cirrhosis and reinfection.
Diabetic Kidney Disease: Finerenone, Nonsteroidal MRAs, and the FIDELIO/FIGARO Evidence
Finerenone, the first nonsteroidal mineralocorticoid receptor antagonist, has demonstrated cardiorenal benefit in DKD beyond SGLT2 inhibitors and RAS blockade. This review covers the FIDELIO-DKD and FIGARO-DKD trials, practical implementation, and the emerging multi-pillar approach to DKD management.
Multiple Sclerosis: Disease-Modifying Therapy Selection Algorithm
The MS treatment landscape now includes over 20 disease-modifying therapies with distinct efficacy, safety, and monitoring profiles. This review provides an evidence-based algorithm for DMT selection in relapsing and progressive MS, incorporating the escalation versus early high-efficacy treatment debate.
Pancreatic Cancer: Early Detection Biomarkers and Treatment Advances
Pancreatic ductal adenocarcinoma remains the third leading cause of cancer death with a 12% five-year survival rate. This review covers emerging early detection strategies, CA 19-9 limitations, the FOLFIRINOX and gemcitabine/nab-paclitaxel evidence, and emerging immunotherapy approaches.
Sickle Cell Disease: Voxelotor, Crizanlizumab, and Gene Therapy
Three novel therapies for sickle cell disease were approved between 2019-2023, and two gene therapies now offer the possibility of functional cure. This review covers voxelotor, crizanlizumab, and L-glutamine evidence, along with the pivotal lovotibeglogene autotemcel and exagamglogene autotemcel data.
Post-COVID Conditions: Clinical Assessment and Management Framework
Post-COVID conditions affect an estimated 10-20% of SARS-CoV-2 infections and encompass over 200 symptoms across multiple organ systems. This review provides a systematic evaluation framework, evidence-based management strategies, and guidance on differentiating post-COVID from overlapping diagnoses.
Diabetic Retinopathy Screening: AI-Assisted Imaging and Referral Criteria
Diabetic retinopathy remains the leading cause of blindness among working-age adults. AI-based retinal screening systems now achieve sensitivity exceeding 90% for referable disease, enabling point-of-care screening in primary care settings with immediate results.
Free Clinical Tools Every Physician Should Know About in 2026
The landscape of free clinical tools has expanded significantly. Here is a practical overview of what is available at no cost for point-of-care reference, evidence synthesis, drug interactions, and more.
Beyond Traditional Medical References: The Evolution of Clinical Decision Support
From textbooks to UpToDate to search-based tools to clinical intelligence platforms — each generation solved problems the last could not. Here is what changed and why it matters.
The Complete Guide to Clinical Decision Support in 2026
A definitive guide to clinical decision support tools in 2026 — covering the history, current landscape, evaluation criteria, citation verification, cross-system reasoning, and future directions of CDS technology for physicians.
Beyond Single-Specialty Answers: Why Cross-System Reasoning Matters
A 58-year-old with type 2 diabetes, eGFR 38, and new atrial fibrillation needs anticoagulation. The cardiology answer, the nephrology answer, and the endocrinology answer are three different answers. Your patient needs one.
What to Look for in a Clinical Decision Support Tool in 2026
Five years ago, clinical decision support meant UpToDate. The landscape in 2026 looks different. Here is a framework for evaluating tools based on what actually matters when you are standing in front of a patient.
Showing 1–17 of 17 articles